Milestone Scientific Inc.(MLSS)Earnings, Financials & Key Ratios
MLSS•AMEX
$0.40
$32M mkt cap·Price updated May 6, 2026
AboutMilestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.Show more
- Revenue$9M-12.2%
- EBITDA-$7M+4.6%
- Net Income-$5M+32.0%
- EPS (Diluted)-0.06+37.9%
- Gross Margin74.56%+7.9%
- EBITDA Margin-77.86%-8.6%
- Operating Margin-78.3%-8.3%
- Net Margin-54.62%+22.5%
- ROE-68.09%+11.5%
- ROIC-121.32%+17.8%
- Debt/Equity0.06+21.1%
MLSS Key Insights
Milestone Scientific Inc. (MLSS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MLSS Price & Volume
Milestone Scientific Inc. (MLSS) stock price & volume — 10-year historical chart
Loading chart...
MLSS Growth Metrics
Milestone Scientific Inc. (MLSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.79%
5 Years0.6%
3 Years-5.74%
TTM7.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.94%
Return on Capital
10 Years-92.65%
5 Years-72.17%
3 Years-78.44%
Last Year-94.19%
MLSS Peer Comparison
Milestone Scientific Inc. (MLSS) competitors in Drug delivery and infusion consumables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XRAY | 2.23B | 11.14 | -3.71 | -2.98% | -17.06% | -41.19% | 1.84 | |
 HSIC | 8.31B | 72.44 | 22.15 | 4.03% | 3.02% | 8.24% | 0.77 | |
 NVST | 4.5B | 27.06 | 96.64 | 8.32% | 2.41% | 2.18% | 0.55 | |
 ALGN | 12.46B | 173.94 | 30.79 | 0.9% | 10.5% | 10.7% | 0.03 | |
 SRDX | 614.51M | 42.98 | -52.41 | -4.91% | -14.59% | -15.59% | 0.28 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 |
Compare MLSS vs Peers
Milestone Scientific Inc. (MLSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLSS Income Statement
Milestone Scientific Inc. (MLSS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.48M | 11.28M | 9.62M | 8.37M | 5.44M | 10.3M | 8.81M | 9.83M | 8.63M | 9.08M |
| Revenue Growth % | 10.43% | 7.63% | -14.71% | -12.97% | -35.07% | 89.52% | -14.54% | 11.6% | -12.19% | 7.84% |
| Cost of Goods Sold | 4.18M | 4.31M | 5.19M | 2.66M | 1.82M | 3.99M | 3.91M | 3.03M | 2.2M | 2.47M |
| COGS % of Revenue | 39.84% | 38.23% | 53.95% | 31.72% | 33.4% | 38.75% | 44.35% | 30.88% | 25.44% | - |
| Gross Profit | 6.31M▲ 0% | 6.97M▲ 10.5% | 4.43M▼ 36.4% | 5.72M▲ 29.0% | 3.62M▼ 36.7% | 6.31M▲ 74.3% | 4.9M▼ 22.4% | 6.79M▲ 38.6% | 6.43M▼ 5.3% | 6.61M▲ 0% |
| Gross Margin % | 60.16% | 61.77% | 46.05% | 68.28% | 66.6% | 61.25% | 55.65% | 69.12% | 74.56% | 72.8% |
| Gross Profit Growth % | -2.12% | 10.51% | -36.42% | 29.04% | -36.67% | 74.3% | -22.36% | 38.6% | -5.27% | - |
| Operating Expenses | 12.82M | 12.2M | 10.89M | 9.72M | 11.07M | 13.69M | 13.73M | 13.9M | 13.19M | 13.61M |
| OpEx % of Revenue | 122.31% | 108.17% | 113.19% | 116.03% | 203.68% | 132.86% | 155.9% | 141.43% | 152.86% | - |
| Selling, General & Admin | 11.55M | 11.93M | 10.65M | 9.53M | 0 | 0 | 0 | 0 | 0 | 9.61M |
| SG&A % of Revenue | 110.19% | 105.75% | 110.63% | 113.77% | - | - | - | - | - | - |
| Research & Development | 1.27M | 272.75K | 245.64K | 189.92K | 307.85K | 878.21K | 1.15M | 701.38K | 858.77K | 870.5K |
| R&D % of Revenue | 12.12% | 2.42% | 2.55% | 2.27% | 5.66% | 8.52% | 13.06% | 7.14% | 9.95% | - |
| Other Operating Expenses | -5.09K | -4.93K | -7.23K | 0 | 10.77M | 12.81M | 12.58M | 13.2M | 12.33M | 1.05M |
| Operating Income | -6.51M▲ 0% | -5.23M▲ 19.6% | -8M▼ 52.8% | -4M▲ 50.0% | -7.45M▼ 86.4% | -7.38M▲ 1.0% | -8.83M▼ 19.6% | -7.11M▲ 19.5% | -6.76M▲ 4.9% | -6.99M▲ 0% |
| Operating Margin % | -62.14% | -46.4% | -83.14% | -47.75% | -137.08% | -71.6% | -100.24% | -72.31% | -78.3% | -77% |
| Operating Income Growth % | -113.1% | 19.64% | -52.82% | 50.01% | -86.37% | 1% | -19.64% | 19.5% | 4.92% | - |
| EBITDA | -6.35M | -4.66M | -7.12M | -3.74M | -7.36M | -7.3M | -8.76M | -7.04M | -6.72M | -6.86M |
| EBITDA Margin % | -60.59% | -41.32% | -73.98% | -44.69% | -135.31% | -70.89% | -99.52% | -71.68% | -77.86% | -75.47% |
| EBITDA Growth % | -114.59% | 26.6% | -52.71% | 47.42% | -96.58% | 0.71% | -19.97% | 19.62% | 4.61% | -2.87% |
| D&A (Non-Cash Add-back) | 163.37K | 573.15K | 881.28K | 256.47K | 95.95K | 73.83K | 63.84K | 62.32K | 37.45K | 138.82K |
| EBIT | -6.51M | -5.23M | -6.46M | -7.64M | -7.45M | -7.38M | -8.83M | -7.11M | -6.76M | -6.99M |
| Net Interest Income | 1.28K | 9.3K | 7.45K | 1.54K | -18.08K | -16.36K | 54.61K | 125.53K | 60.27K | 19.55K |
| Interest Income | 1.28K | 9.3K | 7.45K | 1.54K | 0 | 0 | 54.61K | 125.53K | 60.27K | 19.55K |
| Interest Expense | 0 | 0 | 0 | 0 | 18.08K | 16.36K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.8K | 4.37K | 215 | -3.56M | 79.81K | 502.41K | 54.61K | 125.53K | 2.04M | 19.55K |
| Pretax Income | -6.52M▲ 0% | -5.23M▲ 19.8% | -8M▼ 52.9% | -7.56M▲ 5.5% | -7.37M▲ 2.5% | -6.88M▲ 6.7% | -8.77M▼ 27.6% | -6.98M▲ 20.4% | -4.71M▲ 32.5% | -6.97M▲ 0% |
| Pretax Margin % | -62.18% | -46.36% | -83.13% | -90.3% | -135.61% | -66.73% | -99.62% | -71.04% | -54.62% | -76.78% |
| Income Tax | -19.1K | 19.09K | 23.99K | 18.13K | 15.5K | 333 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.29% | -0.37% | -0.3% | -0.24% | -0.21% | -0% | 0% | 0% | 0% | 0% |
| Net Income | -5.95M▲ 0% | -5.19M▲ 12.8% | -7.43M▼ 43.3% | -7.52M▼ 1.2% | -7.34M▲ 2.5% | -6.82M▲ 7.1% | -8.71M▼ 27.7% | -6.93M▲ 20.4% | -4.71M▲ 32.0% | -6.97M▲ 0% |
| Net Margin % | -56.73% | -45.97% | -77.24% | -89.85% | -134.94% | -66.17% | -98.87% | -70.51% | -54.62% | -76.78% |
| Net Income Growth % | -8.76% | 12.78% | -43.28% | -1.25% | 2.49% | 7.07% | -27.69% | 20.41% | 31.97% | -50.9% |
| Net Income (Continuing) | -7.29M | -5.37M | -7.69M | -7.58M | -7.39M | -6.88M | -8.77M | -6.98M | -4.71M | -6.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 36.11K | 256.74K | -11.4K | -67.27K | -94.43K | -152.54K | -219.28K | 0 | 0 | 0 |
| EPS (Diluted) | -0.22▲ 0% | -0.16▲ 27.3% | -0.21▼ 31.2% | -0.17▲ 19.0% | -0.12▲ 29.4% | -0.10▲ 16.7% | -0.12▼ 20.0% | -0.10▲ 20.7% | -0.06▲ 37.9% | -0.09▲ 0% |
| EPS Growth % | 15.38% | 27.27% | -31.25% | 19.05% | 29.41% | 16.67% | -20% | 20.67% | 37.92% | -41.94% |
| EPS (Basic) | -0.22 | -0.16 | -0.21 | -0.17 | -0.12 | -0.10 | -0.12 | -0.10 | -0.06 | - |
| Diluted Shares Outstanding | 26.97M | 32.7M | 35.3M | 45.74M | 63.06M | 68.83M | 70.61M | 72.78M | 79.79M | 82.05M |
| Basic Shares Outstanding | 26.97M | 32.7M | 35.3M | 45.74M | 63.06M | 68.83M | 70.61M | 72.78M | 79.79M | 82.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MLSS Balance Sheet
Milestone Scientific Inc. (MLSS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.71M | 12.02M | 5.86M | 6.08M | 18.55M | 18.93M | 12.97M | 10.79M | 9.29M | 7.63M |
| Cash & Short-Term Investments | 3.6M | 2.64M | 743.43K | 1.52M | 14.22M | 14.76M | 8.72M | 5.95M | 3.26M | 1.27M |
| Cash Only | 3.6M | 2.64M | 743.43K | 1.52M | 14.22M | 14.76M | 8.72M | 2.98M | 3.26M | 1.27M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.98M | 0 | 0 |
| Accounts Receivable | 3.52M | 3.26M | 2.08M | 1.71M | 1.08M | 943.27K | 693.72K | 312.66K | 475.38K | 690.63K |
| Days Sales Outstanding | 122.47 | 105.5 | 78.84 | 74.56 | 72.54 | 33.41 | 28.75 | 11.61 | 20.11 | 22.55 |
| Inventory | 4.6M | 3.38M | 1.92M | 1.62M | 2.42M | 1.54M | 1.79M | 2.64M | 3.71M | 3.9M |
| Days Inventory Outstanding | 402.34 | 286.01 | 135.08 | 222.69 | 486.45 | 140.92 | 167.53 | 317.3 | 617.36 | 571.73 |
| Other Current Assets | 1.33M | 2.31M | 698.78K | 710.66K | 414.2K | 1.31M | 1.33M | 1.37M | 564.64K | 1.13M |
| Total Non-Current Assets | 836.84K | 3.61M | 544.71K | 479.12K | 1.02M | 875.99K | 731.58K | 577.04K | 510.52K | 420K |
| Property, Plant & Equipment | 159.03K | 141.76K | 82.56K | 60.95K | 663.18K | 574.22K | 479.48K | 374.26K | 337.96K | 282.36K |
| Fixed Asset Turnover | 65.91x | 79.58x | 116.55x | 137.39x | 8.20x | 17.95x | 18.37x | 26.26x | 25.54x | 29.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 660.46K | 2.79M | 435.27K | 382.26K | 329.25K | 277.62K | 227.96K | 178.64K | 148.4K | 113.49K |
| Long-Term Investments | 0 | 650K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 17.36K | 676.88K | 26.88K | 35.91K | 24.15K | 24.15K | 24.15K | 24.15K | 24.15K | 96.6K |
| Total Assets | 13.55M▲ 0% | 15.63M▲ 15.3% | 6.4M▼ 59.0% | 6.56M▲ 2.4% | 19.57M▲ 198.5% | 19.81M▲ 1.2% | 13.7M▼ 30.8% | 11.37M▼ 17.0% | 9.8M▼ 13.8% | 8.05M▲ 0% |
| Asset Turnover | 0.77x | 0.72x | 1.50x | 1.28x | 0.28x | 0.52x | 0.64x | 0.86x | 0.88x | 0.95x |
| Asset Growth % | 5.79% | 15.34% | -59.04% | 2.43% | 198.51% | 1.22% | -30.83% | -17.01% | -13.85% | -61.13% |
| Total Current Liabilities | 5.01M | 6.73M | 4.87M | 4.93M | 2.88M | 3.1M | 3.3M | 3.08M | 3.74M | 3.77M |
| Accounts Payable | 2.58M | 977.62K | 2.87M | 2.74M | 868.11K | 1.18M | 1.91M | 1.1M | 1.02M | 1.96M |
| Days Payables Outstanding | 225.2 | 82.74 | 201.76 | 376.27 | 174.49 | 107.53 | 178.17 | 132.31 | 169.82 | 222.83 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 276.18K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1M | 2.48M | 521.8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 340.48K | 242.59K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 2.54x | 1.79x | 1.20x | 1.23x | 6.45x | 6.11x | 3.93x | 3.51x | 2.48x | 2.48x |
| Quick Ratio | 1.62x | 1.28x | 0.81x | 0.90x | 5.61x | 5.62x | 3.39x | 2.65x | 1.49x | 1.49x |
| Cash Conversion Cycle | 299.61 | 308.77 | 12.17 | -79.03 | 384.51 | 66.8 | 18.11 | 196.6 | 467.65 | 371.45 |
| Total Non-Current Liabilities | 36.11K | 1.4M | 0 | 0 | 586.59K | 497.04K | 395.98K | 282.29K | 220.25K | 942.89K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 800K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 586.59K | 497.04K | 395.98K | 282.29K | 220.25K | 740.71K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | -1 |
| Total Liabilities | 5.01M | 8.13M | 4.87M | 4.93M | 3.46M | 3.59M | 3.7M | 3.36M | 3.96M | 4.71M |
| Total Debt | 0 | 0 | 0 | 15.98K | 942.6K | 586.59K | 497.04K | 395.98K | 349.05K | 1.09M |
| Net Debt | -3.6M | -2.64M | -743.43K | -1.5M | -13.28M | -14.18M | -8.22M | -2.58M | -2.91M | -187.76K |
| Debt / Equity | - | - | - | 0.01x | 0.06x | 0.04x | 0.05x | 0.05x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.03x |
| Interest Coverage | - | - | - | - | -412.21x | -451.01x | - | - | - | - |
| Total Equity | 8.54M▲ 0% | 7.5M▼ 12.1% | 1.53M▼ 79.6% | 1.63M▲ 6.6% | 16.11M▲ 889.0% | 16.22M▲ 0.7% | 10.01M▼ 38.3% | 8.01M▼ 19.9% | 5.83M▼ 27.2% | 3.34M▲ 0% |
| Equity Growth % | -6.86% | -12.13% | -79.63% | 6.57% | 888.98% | 0.67% | -38.29% | -19.93% | -27.21% | -122.13% |
| Book Value per Share | 0.32 | 0.23 | 0.04 | 0.04 | 0.26 | 0.24 | 0.14 | 0.11 | 0.07 | 0.04 |
| Total Shareholders' Equity | 8.5M | 7.24M | 1.54M | 1.7M | 16.2M | 16.37M | 10.23M | 8.01M | 5.83M | 3.34M |
| Common Stock | 31.72K | 34.59K | 36.33K | 49.41K | 64.17K | 68.15K | 69.31K | 75.88K | 78.05K | 78.59K |
| Retained Earnings | -73.38M | -78.57M | -86M | -93.52M | -100.89M | -107.7M | -116.41M | -123.34M | -128.05M | -131.53M |
| Treasury Stock | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K | -911.52K |
| Accumulated OCI | -659.14K | -721.62K | -788.68K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 36.11K | 256.74K | -11.4K | -67.27K | -94.43K | -152.54K | -219.28K | 0 | 0 | 0 |
MLSS Cash Flow Statement
Milestone Scientific Inc. (MLSS) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.4M | -1.23M | -1.63M | -1.78M | -6.98M | -4.02M | -6.03M | -5.33M | -2.92M | -2.92M |
| Operating CF Margin % | -51.5% | -10.9% | -16.92% | -21.25% | -128.46% | -38.99% | -68.5% | -54.2% | -33.83% | - |
| Operating CF Growth % | -83.23% | 77.23% | -32.43% | -9.29% | -292.57% | 42.48% | -50.14% | 11.7% | 45.18% | -321.68% |
| Net Income | -7.29M | -5.37M | -7.69M | -7.58M | -7.39M | -6.88M | -8.77M | -6.93M | -4.71M | -6.97M |
| Depreciation & Amortization | 163.37K | 573.15K | 881.28K | 256.47K | 95.95K | 73.83K | 144.38K | 150.36K | 134.84K | 163.46K |
| Stock-Based Compensation | 1.85M | 651.41K | 409.02K | 183.89K | 1.35M | 1.58M | 1.82M | 1.88M | 1.71M | 1.71M |
| Deferred Taxes | -1.05M | 182.76K | 260.13K | 0 | -97.89K | -518.77K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.85M | 157.58K | 2.74M | 3.55M | 1.67M | 652.76K | 1.33M | 968.16K | 579.8K | 321.49K |
| Working Capital Changes | -914.04K | 2.58M | 1.77M | 1.81M | -1.81M | 1.07M | -549.72K | -1.4M | -631K | -476.17K |
| Change in Receivables | -1.09M | 256.02K | -635.48K | 367.79K | 630.01K | 137.38K | 249.56K | 309.94K | -162.71K | 253.57K |
| Change in Inventory | -509.46K | 1M | 914.61K | 300.54K | -799.67K | 878.67K | -833.12K | -1.1M | -1.08M | 36.46K |
| Change in Payables | 486.35K | -612.96K | 905.94K | 16.89K | -1.87M | 308.18K | 729.94K | -806.11K | 414.59K | -1.04M |
| Cash from Investing | 8.21K | -199.18K | -15.42K | -9.92K | -21.44K | -15.19K | -8.53K | -2.97M | 2.97M | -2.98M |
| Capital Expenditures | -30.96K | -199.18K | -7.4K | -9.92K | -21.44K | -15.19K | -8.53K | -4.88K | -10.12K | -2.71K |
| CapEx % of Revenue | 0.3% | 1.77% | 0.08% | 0.12% | 0.39% | 0.15% | 0.1% | 0.05% | 0.12% | - |
| Acquisitions | 39.16K | 0 | -8.02K | 0 | 0 | 0 | 0 | 2.97M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 39.16K | -193.17K | 0 | 0 | 0 | 0 | 0 | -2.97M | 0 | -2.98M |
| Cash from Financing | 4.8M | 463.34K | -250K | 2.56M | 19.71M | 4.57M | -8.54K | 2.56M | 233.77K | 789.19K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 268.56K | -8.65K | -8.54K | -9.37K | -10.14K | 789.19K |
| Equity Issued (Net) | 1000K | 400.84K | 0 | 1000K | 0 | 0 | 0 | 1000K | 192.16K | -192.16K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -250K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 62.5K | -250K | 337.5K | 19.45M | 4.6M | 0 | 0 | 51.75K | 192.16K |
| Net Change in Cash | -592.15K▲ 0% | -965.27K▼ 63.0% | -1.89M▼ 96.2% | 772.84K▲ 140.8% | 12.71M▲ 1544.3% | 540.43K▼ 95.7% | -6.05M▼ 1219.3% | -5.74M▲ 5.1% | 280.35K▲ 104.9% | -4.48M▲ 0% |
| Free Cash Flow | -5.43M▲ 0% | -1.43M▲ 73.7% | -1.64M▼ 14.5% | -1.79M▼ 9.4% | -7.01M▼ 291.6% | -4.03M▲ 42.4% | -6.04M▼ 49.8% | -5.33M▲ 11.7% | -2.93M▲ 45.0% | -5.26M▲ 0% |
| FCF Margin % | -51.8% | -12.66% | -17% | -21.36% | -128.86% | -39.14% | -68.6% | -54.25% | -33.95% | -57.91% |
| FCF Growth % | -79.56% | 73.69% | -14.48% | -9.4% | -291.59% | 42.44% | -49.79% | 11.75% | 45.04% | -91.72% |
| FCF per Share | -0.20 | -0.04 | -0.05 | -0.04 | -0.11 | -0.06 | -0.09 | -0.07 | -0.04 | -0.04 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.24x | 0.22x | 0.24x | 0.95x | 0.59x | 0.69x | 0.77x | 0.62x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLSS Key Ratios
Milestone Scientific Inc. (MLSS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -67.19% | -64.69% | -164.62% | -476.7% | -82.74% | -42.19% | -66.4% | -76.91% | -68.09% | -208.8% |
| Return on Invested Capital (ROIC) | -98.64% | -80.14% | -212.43% | -656.91% | -378.46% | -227.58% | -346.1% | -147.66% | -121.32% | -121.32% |
| Gross Margin | 60.16% | 61.77% | 46.05% | 68.28% | 66.6% | 61.25% | 55.65% | 69.12% | 74.56% | 72.8% |
| Net Margin | -56.73% | -45.97% | -77.24% | -89.85% | -134.94% | -66.17% | -98.87% | -70.51% | -54.62% | -76.78% |
| Debt / Equity | - | - | - | 0.01x | 0.06x | 0.04x | 0.05x | 0.05x | 0.06x | 0.06x |
| Interest Coverage | - | - | - | - | -412.21x | -451.01x | - | - | - | - |
| FCF Conversion | 0.91x | 0.24x | 0.22x | 0.24x | 0.95x | 0.59x | 0.69x | 0.77x | 0.62x | 0.75x |
| Revenue Growth | 10.43% | 7.63% | -14.71% | -12.97% | -35.07% | 89.52% | -14.54% | 11.6% | -12.19% | 7.84% |
MLSS Frequently Asked Questions
Milestone Scientific Inc. (MLSS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Milestone Scientific Inc. (MLSS) reported $9.1M in revenue for fiscal year 2024. This represents a 2928% increase from $0.3M in 1996.
Milestone Scientific Inc. (MLSS) saw revenue decline by 12.2% over the past year.
Milestone Scientific Inc. (MLSS) reported a net loss of $7.0M for fiscal year 2024.
Dividend & Returns
Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -68.1%. Negative ROE indicates the company is unprofitable.
Milestone Scientific Inc. (MLSS) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More MLSS
Milestone Scientific Inc. (MLSS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates